384 related articles for article (PubMed ID: 19474787)
1. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
[TBL] [Abstract][Full Text] [Related]
2. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
3. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
Pasanen MK; Fredrikson H; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2007 Dec; 82(6):726-33. PubMed ID: 17473846
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
6. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
[TBL] [Abstract][Full Text] [Related]
7. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
[TBL] [Abstract][Full Text] [Related]
8. Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.
DeGorter MK; Urquhart BL; Gradhand U; Tirona RG; Kim RB
J Clin Pharmacol; 2012 Nov; 52(11):1689-97. PubMed ID: 22167570
[TBL] [Abstract][Full Text] [Related]
9. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
[TBL] [Abstract][Full Text] [Related]
10. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.
Tomlinson B; Hu M; Lee VW; Lui SS; Chu TT; Poon EW; Ko GT; Baum L; Tam LS; Li EK
Clin Pharmacol Ther; 2010 May; 87(5):558-62. PubMed ID: 20130569
[TBL] [Abstract][Full Text] [Related]
11. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.
Hu M; To KK; Mak VW; Tomlinson B
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):49-62. PubMed ID: 21091277
[TBL] [Abstract][Full Text] [Related]
12. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
13. The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males.
Lou XY; Zhang W; Wang G; Hu DL; Guo D; Tan ZR; Zhou HH; Chen Y; Bao HH
Pharmazie; 2014 Oct; 69(10):775-9. PubMed ID: 25985569
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
Lee E; Ryan S; Birmingham B; Zalikowski J; March R; Ambrose H; Moore R; Lee C; Chen Y; Schneck D
Clin Pharmacol Ther; 2005 Oct; 78(4):330-41. PubMed ID: 16198652
[TBL] [Abstract][Full Text] [Related]
16. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
Choi JH; Lee MG; Cho JY; Lee JE; Kim KH; Park K
Clin Pharmacol Ther; 2008 Feb; 83(2):251-7. PubMed ID: 17568401
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
18. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
[TBL] [Abstract][Full Text] [Related]
19. Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Piscitelli S; Kim J; Gould E; Lou Y; White S; de Serres M; Johnson M; Zhou XJ; Pietropaolo K; Mayers D
Br J Clin Pharmacol; 2012 Aug; 74(2):336-45. PubMed ID: 22288567
[TBL] [Abstract][Full Text] [Related]
20. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
